The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
about
In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?The endocannabinoid system as an emerging target of pharmacotherapyAM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic painTherapeutic potential of monoacylglycerol lipase inhibitorsActions of N-arachidonyl-glycine in a rat inflammatory pain modelModulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamideTargeting cannabinoid agonists for inflammatory and neuropathic painThe synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic painAnandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: involvement of cannabinoid CB1 and vanilloid VR1 receptorsRecent data on cannabinoids and their pharmacological implications in neuropathic pain.Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain.Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedsideThe antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioidsPharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic painCannabis in palliative medicine: improving care and reducing opioid-related morbidity.Cannabis and the brain.Modulation of pain transmission by G-protein-coupled receptors.Cannabinoids inhibit acid-sensing ion channel currents in rat dorsal root ganglion neurons.Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative painTreating pain in multiple sclerosis.Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in ratsCannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neuronsLocal activation of cannabinoid CB₁ receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents.Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons.Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy.Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury painCannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley ratsCentrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception.Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.Opposite function of dopamine D1 and N-methyl-D-aspartate receptors in striatal cannabinoid-mediated signaling.Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain.Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injuryThe neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat.TRPA1 mediates the hypothermic action of acetaminophen.Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.Emerging analgesics in cancer pain management.The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy
P2860
Q24564956-1305BB41-9E32-4A0A-A0E6-ED551771D2E4Q24648473-AD803B3D-E265-409E-BC9A-9F264D73AA49Q24675554-19FD6201-7EE7-4125-8FF6-004EF894E030Q26991513-9F4EE44A-5DD0-4F09-8A41-A369F290144DQ27498684-A557B54F-BA8D-47CD-9542-692B83577428Q28248981-37395300-51C0-4367-8740-91EB2FDBF897Q28307619-3454683E-63C8-4DA3-8A27-6D97C39ADDCCQ28366593-11163CE6-A2C3-4B49-B25C-D8DFEA4467CBQ28581593-1A483A0A-48A9-4967-8732-A23FC6FDA0DDQ33527067-34355484-1720-44AD-9675-E5247440262DQ33560467-429A4626-31B5-472B-A763-64B868A68326Q34019573-697D4F9C-5B88-441C-831E-CA05BB4B9184Q34059667-A17320F8-BF0A-4F82-8B12-E33CD47924B5Q34118976-CC6A9AE5-2224-4207-ABE3-07F16C1842C6Q34173898-709CD934-2C6D-41ED-B7F4-B641EA2E9DE9Q34199483-567AADBA-6E80-420A-89AB-EB5A5313EDCBQ34247711-75BD615F-1085-4CAF-BBD2-35BEFD6E7F9BQ34429295-09017952-DCA2-4BF9-A9EA-5F53A957ADCDQ34549363-E37B946A-FABD-4459-BDE7-C360D0F6571FQ34606612-0FC52FB7-47F5-4144-9822-1CC25BCECC69Q34632301-0A7B54D6-9E51-4BB1-A857-B6F5AAC79DE4Q34802605-92B5E63E-2548-472F-9855-F28ADA4A7F71Q35047139-51A9CD79-204A-4D85-977C-ABD5FFDEE1B2Q35047740-C304BE11-597B-4F52-8FEE-AD68906E6B6DQ35087509-EB5B92A3-DB60-4806-A1E7-0BBDB665E930Q35138445-F38E4BCD-D4F8-494C-821E-541CD6513F64Q35175618-BB7BDD00-EDD0-4807-87C2-D81B34A32862Q35223942-D5274EFD-F5DB-4D2E-A59D-32C853D22843Q35421957-BDA4EC33-9EE6-4717-943A-91052AA80179Q35545219-0F641613-78D8-4A4A-9E9E-E5895501FA20Q35575588-3371645A-9E6A-4D91-8E84-4C03A121EE16Q35600288-110A0B9E-4C96-429B-AFEB-9298AD3E4493Q35689152-2460852F-3C71-47B7-A285-AE501D62EBF2Q35745959-BFAF629C-4FF5-4794-A6DA-34A91C31BAD2Q35774635-3B18EFD8-203A-44CD-A7FF-017CF8D6B244Q35854891-40999F89-75EC-4D45-A5A0-6E37A38DCD59Q35942820-BE2EF7AE-FEAB-4FB0-A803-63B67066AB79Q36015427-3BA9067D-F018-47B9-84D2-03312846E338Q36066043-F643E51E-AE2A-40DE-82D1-AE0CF0AC89D2Q36094329-B1A9C96C-9AB1-499D-9833-F767DFC8A16A
P2860
The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
The role of central and periph ...... n a model of neuropathic pain.
@en
The role of central and periph ...... n a model of neuropathic pain.
@nl
type
label
The role of central and periph ...... n a model of neuropathic pain.
@en
The role of central and periph ...... n a model of neuropathic pain.
@nl
prefLabel
The role of central and periph ...... n a model of neuropathic pain.
@en
The role of central and periph ...... n a model of neuropathic pain.
@nl
P2093
P921
P1433
P1476
The role of central and periph ...... n a model of neuropathic pain.
@en
P2093
A Kesingland
P304
P356
10.1016/S0304-3959(00)00474-7
P407
P577
2001-05-01T00:00:00Z